 |
217 Diseases |  |
226 Trials |
|
226 Trials |  |
3828 News |  |
| «12...4567891011121314...4950» |
- ||| Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New trial: easy laugh: To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study (clinicaltrials.gov) - Dec 19, 2022
P=N/A, N=204, Recruiting, Sponsor: Shanghai Pudong Hospital
- || P2 data, Journal: Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial. (Pubmed Central) - Dec 17, 2022
P2
However, additional metformin treatment with chemotherapy would prevent TC and LDL-C increase after NAT. Trial Registration ClinicalTrials.gov Identifier: NCT01929811.
- || VesiGel (mitomycin intravesicular) / UroGen
Retrospective data, Review, Journal: A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer. (Pubmed Central) - Dec 16, 2022
Despite the lack of long-term outcomes, chemoablation appears to be a promising treatment option for well-selected NMIBC patients and can potentially help avoid unnecessary TURBT, specifically in some elderly patients with intermediate-risk NMIBC. Further well-designed studies with larger cohorts are necessary to address the differential tolerability and long-term anticancer efficacy of this resurging approach.
- | ifosfamide / Generic mfg., epirubicin / Generic mfg.
Journal: Malignant perivascular epithelioid cell tumor (PEComa) of the uterus. (Pubmed Central) - Dec 16, 2022
For patients with malignant uterine PEComas, removal of both primary lesions and metastatic foci, if any, needs to be attempted. Postoperative chemotherapy or radiotherapy should also be considered in patients with distant metastases or positive lymph nodes.
- ||||| Tecentriq (atezolizumab) / Roche
Enrollment closed, Combination therapy: IMpassion030: A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (clinicaltrials.gov) - Dec 14, 2022
P3, N=2300, Active, not recruiting, Sponsor: Hoffmann-La Roche
Postoperative chemotherapy or radiotherapy should also be considered in patients with distant metastases or positive lymph nodes. Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg.
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma. (Available On Demand; Poster Board No. L3) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_574;
mCTX MT extends PFS and OS of mPDAC pts not progressing after at least 6 months of CT with unremarkable toxicity in our exploratory non-randomized analysis. >CT: chemotherapy; CA19.9: Carbohydrate Antigen 19.9; PAXG/PEXG/PEFG/PDXG: Cisplatin, Nab-Paclitaxel or Epirubicin or Docetaxel, Capecitabine or 5-fluorouracil, Gemcitabine.
- zolbetuximab (IMAB362) / Astellas
Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab. (Available On Demand; Poster Board No. L12) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_284;
P1, P2
Treatment with zolbetuximab is associated with tumor and peripheral biomarker changes related to its proposed mechanism of action. Clinical responses observed in pts treated with zolbetuximab and mFOLFOX6 are associated with correlative biomarkers of activity including rapid deep molecular responses (ctDNA).
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI. (Available On Demand; Poster Board No. C6) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_134;
A phase III French intergroup study demonstrated a longer time to treatment failure, improved toxicity profile, and no difference in median OS when using FOLFIRI, compared to epirubicin, cisplatin, and capecitabine (ECX)... FOLFIRI had comparable efficacy to other first-line regimens in patients with AGC.
- Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis. (Available On Demand; Poster Board No. B14) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_121;
P3
Oncologic and operative outcomes were consistent with optimum modern benchmarks. These data strongly suggest non-inferiority and support equipoise in clinical decision making in modern practice.
- Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis. (Available On Demand) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_115;
P3
Oncologic and operative outcomes were consistent with optimum modern benchmarks. These data strongly suggest non-inferiority and support equipoise in clinical decision making in modern practice.
- | idarubicin hydrochloride / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. (Pubmed Central) - Dec 13, 2022
TACE with IDA-MS could also significantly enhance the sensitivity of anti-PD1 immunotherapy, improve the expression of CD8 T cells, and activate the tumor immune microenvironment in HCC. This study provides a new approach for TACE therapy and immunotherapy and illuminates the future of HCC treatment.
- | Journal: DNA damage independent inhibition of NF-kB transcription by anthracyclines. (Pubmed Central) - Dec 9, 2022
The anthracycline variants Aclarubicin, Doxorubicinone and the newly developed Dimethyl-doxorubicin, which share anticancer properties with the other anthracyclines but do not induce DNA damage, also suppressed inflammation, thus uncoupling DNA damage from the effects on inflammation. These findings have implications for anticancer therapy and for the development of novel anti-inflammatory drugs with limited side effects for life-threatening conditions such as sepsis.
- | oxaliplatin / Generic mfg., epirubicin / Generic mfg.
Journal: Super-selective transcatheter vesical arterial chemoembolization with drug-loaded beads for muscle-invasive bladder cancer with hematuria. (Pubmed Central) - Dec 9, 2022
These findings have implications for anticancer therapy and for the development of novel anti-inflammatory drugs with limited side effects for life-threatening conditions such as sepsis. DEB-TACE is safe and effective for treating muscle-invasive bladder cancer with hematuria, preserving bladder function and improving the QOL.
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Journal: NUSAP1 and PCLAF (KIA0101) Downregulation by Neoadjuvant Therapy is Associated with Better Therapeutic Outcomes and Survival in Breast Cancer. (Pubmed Central) - Dec 9, 2022
These genes are involved in the regulation of mitotic division. The downregulation of NUSAP1 and PCLAF after NCT is associated with the tumor response to chemotherapy and patient survival.
- | cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Journal: Four Genes Predictive for the Severity of Hematological Damage Reveal a Similar Response after X Irradiation and Chemotherapy. (Pubmed Central) - Dec 9, 2022
In summary, the pattern of up-regulated GE changes observed in all CTX patients and down-regulated GE changes observed in a subgroup of CTX patients appeared comparable with an already identified gene set predictive for the radiation-induced H-ARS. This underlines the significance of in vivo GE measurements in CTX patients, employed as a surrogate model to further validate already identified radiation-induced GE changes predictive for the H-ARS.
- | epirubicin / Generic mfg.
Journal: Epirubicin may enhance the inhibition of hepatocellular carcinoma induced by iodine-125 seeds through downregulating WNT pathway. (Pubmed Central) - Dec 6, 2022
This underlines the significance of in vivo GE measurements in CTX patients, employed as a surrogate model to further validate already identified radiation-induced GE changes predictive for the H-ARS. EPI combined with I induced apoptosis and inhibited the proliferation of HCC cells by LL-37 downregulating the WNT pathway.
- | New trial: Neoadjuvant Effect of Albumin Binding Paclitaxel Compared With Common Paclitaxel in Breast Cancer?an Observational Single Center Study of Clinical Efficacy in Adjuvant Chemotherapy (clinicaltrials.gov) - Dec 5, 2022
P=N/A, N=112, Recruiting, Sponsor: Mei Zhang
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Trial completion date, Trial primary completion date: Reduced Chemotherapy in Low Risk DLBCL (clinicaltrials.gov) - Dec 5, 2022
P4, N=290, Active, not recruiting, Sponsor: Ruijin Hospital
EPI combined with I induced apoptosis and inhibited the proliferation of HCC cells by LL-37 downregulating the WNT pathway. Unknown status --> Active, not recruiting | Trial completion date: Jun 2020 --> Dec 2024 | Trial primary completion date: Apr 2020 --> Oct 2022
- | Journal: Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report. (Pubmed Central) - Dec 2, 2022
The pancreas is a very rare extraosseous location for Ewing's sarcoma. Pancreatic extraosseous Ewing's sarcoma should be regarded as a differential diagnosis of non-urinary originated left flank pain with dysuria in adolescents.
- | Journal, IO biomarker: Comparison of the immunomodulatory potential of platinum-based anti-cancer drugs and anthracyclins on human monocyte-derived cells. (Pubmed Central) - Dec 1, 2022
Furthermore, we found that inflammatory macrophages are more sensitive to doxorubicin-induced cell death than their counterparts.In summary, our results confirm that chemotherapeutic agents acting on a similar basis may have different effects on the anti-tumor immune response. Treatment with optimal dose, combinations, and timing of chemotherapy may determine tumor immunity and the metastatic potential of tumors.
- || Review, Journal: Extraosseous Ewing's sarcoma/peripheral primitive neuroectodermal tumour of the kidney: a case report and literature review. (Pubmed Central) - Dec 1, 2022
Early CEUS was helpful to make an accurate diagnosis. Surgery and adjuvant radiation or chemotherapy administered in a timely manner can prevent further deterioration.
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment open: NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (clinicaltrials.gov) - Nov 30, 2022
P2, N=120, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Surgery and adjuvant radiation or chemotherapy administered in a timely manner can prevent further deterioration. Not yet recruiting --> Recruiting
- paclitaxel / Generic mfg., epirubicin / Generic mfg.
Serum proteins as predictive markers of the response to neoadjuvant chemotherapy for breast cancer () - Nov 30, 2022 - Abstract #DKK2022DKK_2133;
N-cadherin should be emphasized, due to an inverse behaviour with an increase of intensity at t1 in CR and a decrease of intensity at t1 in NR. The present findings lay the foundation to expand the study with a larger patient number.
- Multicenter randomized phase III study of 5‐FU, leucovorin, oxaliplatin, and doxetaxel (FLOT) versus epirubicin, cisplatin, and 5‐FU (ECF) in patients with locally advanced resectable adenocarcinoma of the esophagogastric junction and stomach (Room M8) - Nov 30, 2022 - Abstract #DKK2022DKK_1486;
- | epirubicin / Generic mfg.
Preclinical, Journal: Proteoglycan-4 predicts good prognosis in patients with hepatocellular carcinoma receiving transcatheter arterial chemoembolization and inhibits cancer cell migration in vitro. (Pubmed Central) - Nov 29, 2022
When PRG4 expression was low, starvation treatment impaired the migratory ability of HCC cells and reduced the chemosensitivity of HCC cells to epirubicin...Furthermore, knockdown of PRG4 enhanced EMT, leading to HCC cell migration. PRG4 may serve as a biomarker for HCC patients receiving TACE.
- | epirubicin / Generic mfg.
Journal: Efficacy of Epi-1 Modified Epirubicin and Curcumin Encapsulated Liposomes Targeting-EpCAM in the inhibition of Epithelial Ovarian Cancer cells. (Pubmed Central) - Nov 29, 2022
Also, targeted liposomes downregulated angiogenesis-related proteins to inhibit angiogenesis and thus tumor metastasis. In conclusion, the production of dual drug loaded Epi-1-liposomes is an effective strategy for the treatment of EOC.
- || albumin-bound paclitaxel / Generic mfg.
P2 data, Journal: Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study. (Pubmed Central) - Nov 26, 2022
P4
Nab-paclitaxel followed by dose-dense EC as NAC demonstrates promising anti-tumor activity and acceptable tolerability for patients with TNBC. (ClinicalTrials.gov Identifier: NCT03799679).
- | tamoxifen / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Journal: Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer. (Pubmed Central) - Nov 25, 2022
Circulating cell-free hypomethylated TSTD1 was detected in plasma of Taiwanese breast cancer patients with disease progression and poor chemotherapy efficacy. Our results indicate that promoter hypomethylation and overexpression of TSTD1 in patients with breast cancer are potential biomarkers for poor 5-year overall survival and poor treatment response.
- | epirubicin / Generic mfg.
Journal: Effects of FeO Magnetic Nanoparticle Functionalization with Ionic Liquids and a Double-Chained Surfactant on the Pretreatment of Plasma Samples during Drug Extraction. (Pubmed Central) - Nov 23, 2022
The effectiveness of the developed NP-based extraction phases was tested by applying them for the extraction of epirubicin hydrochloride (EPI) from plasma samples, followed by analysis via liquid chromatography with fluorescence detection (LC-FL)...Additionally, the findings also revealed that the adsorption of analytes depends not only on the coating procedure but also on the type of coating material used to functionalize the NPs. Among the tested structures, didodecyldimethylammonium bromide provided the best performance for the functionalization of NP sorbents previously coated with silica.
- 5-fluorouracil / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Breast cancer and pregnancy :about a series of cases and review of the literature (Exhibition Hall) - Nov 23, 2022 - Abstract #EBCC2022EBCC_482;
Chemotherapy should be avoided during the first trimester, but there are no major fetal risks in the second and third trimesters for combinations such as FEC (5 fluorouracil, epirubicin, cyclophosphamide) and FAC (5 fluorouracil, anthracycline, cyclophosphamide). No hormone therapy or targeted therapy is currently possible during pregcy or breastfeeding.
- Herceptin (trastuzumab) / Roche, EG12014 (trastuzumab biosimilar) / EirGenix, Novartis
A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with Herceptin® as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer (Exhibition Hall) - Nov 23, 2022 - Abstract #EBCC2022EBCC_367;
Neoadjuvant phase: 807 patients were randomized (1:1) into 2 arms receiving epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks for 4 cycles, followed by EG12014 (arm 1) or Herceptin (arm 2) (both at loading dose: 8 mg/kg and maintece dose: 6 mg/kg) and paclitaxel (175 mg/m2) every 3 weeks for 4 cycles. This study demonstrated that EG12014, a proposed trastuzumab biosimilar, matches reference trastuzumab in terms of efficacy, safety, PK and immunogenicity.
- | Enrollment open, Trial completion date, Trial primary completion date: Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids (clinicaltrials.gov) - Nov 22, 2022
P2, N=33, Recruiting, Sponsor: University Hospital Inselspital, Berne
This study demonstrated that EG12014, a proposed trastuzumab biosimilar, matches reference trastuzumab in terms of efficacy, safety, PK and immunogenicity. Not yet recruiting --> Recruiting | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2024 --> Nov 2024
- | 5-fluorouracil / Generic mfg.
Journal, HEOR: Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. (Pubmed Central) - Nov 21, 2022
P2/3
Not yet recruiting --> Recruiting | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2024 --> Nov 2024 For patients with locally advanced resectable tumours, the FLOT chemotherapy is a cost-effective treatment option compared with ECF/ECX in China.
- || dicycloplatin (DCP) - Sopo / Xingda Pharma, Bioplatin
P2 data, Journal: TACE with dicycloplatin in patients with unresectable hepatocellular carcinoma: a multicenter randomized phase II trial. (Pubmed Central) - Nov 19, 2022
• This phase II trial showed that TACE with dicycloplatin alone or plus epirubicin was comparably safe and well tolerable as epirubicin alone. • Significant improvements in ORR, DCR when dicycloplatin was applied, and prolonged PFS when dicycloplatin plus epirubicin was applied were recorded compared with epirubicin alone.
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., epirubicin / Generic mfg.
Journal: Inhibition of EP2 receptor suppresses tumor growth and chemoresistance of gastric cancer. (Pubmed Central) - Nov 19, 2022
This novel study unraveled CAV1 was a downstream target of EP2 receptor. Antagonizing EP2 receptor could be a potential therapeutic target in gastric cancer, in particular those with high EP2 receptor expression.
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed: EORTC 1745-ETF-BCG: Adjuvant Palbociclib in Elderly Patients With Breast Cancer (clinicaltrials.gov) - Nov 17, 2022
P2, N=366, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Antagonizing EP2 receptor could be a potential therapeutic target in gastric cancer, in particular those with high EP2 receptor expression. Recruiting --> Active, not recruiting
- || 5-fluorouracil / Generic mfg.
Clinical, Retrospective data, Review, Journal: The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis. (Pubmed Central) - Nov 16, 2022
Recruiting --> Active, not recruiting The taxane-based triplet regimen of TPF is likely the optimal neoadjuvant chemotherapy regimen for LAGC patients.
- | doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Journal: 2,4-Dinitrophenol as an Uncoupler Augments the Anthracyclines Toxicity against Prostate Cancer Cells. (Pubmed Central) - Nov 16, 2022
The synergistic activity may consist of an inhibition of ATP synthesis and the simultaneous production of toxic amounts of ROS, destroying the mitochondria. Additionally, the sensitivity of the LNCaP cell line to the anthracyclines is relatively higher compared to the other two (PC-3, DU-145).
- || mitomycin / Generic mfg., epirubicin / Generic mfg.
Review, Journal: Systematic review on oncologic outcomes on adjuvant endovesical treatment for non-muscle invasive bladder cancer in patients with solid organ transplant. (Pubmed Central) - Nov 15, 2022
In solid organ transplanted patients under immunosuppressive treatment, both endovesical chemotherapy and BCG are safe, but the level of evidence concerning efficacy in comparison with the general population is low. According to these results, adjuvant treatment should be proposed for NMIC in transplanted patients as in the general population.
- ||| 5-fluorouracil / Generic mfg.
P3 data, Journal: Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. (Pubmed Central) - Nov 15, 2022
P3
According to these results, adjuvant treatment should be proposed for NMIC in transplanted patients as in the general population. Updated results from the GIM2 study support that optimal adjuvant chemotherapy for patients with high-risk early breast cancer should not include fluorouracil and should use a dose-dense schedule.
- ||| Tecentriq (atezolizumab) / Roche
Enrollment closed: neoMono: Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (clinicaltrials.gov) - Nov 9, 2022
P2, N=416, Active, not recruiting, Sponsor: Palleos Healthcare GmbH
Updated results from the GIM2 study support that optimal adjuvant chemotherapy for patients with high-risk early breast cancer should not include fluorouracil and should use a dose-dense schedule. Recruiting --> Active, not recruiting
- | cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Journal: Human clinical trial using diagnostic ultrasound and microbubbles to enhance neoadjuvant chemotherapy in HER2- negative breast cancer. (Pubmed Central) - Nov 8, 2022
Combined therapy did not cause additional toxicity or increase side effects. USMB and chemotherapy can be combined in a clinical setting using commercially available equipment, without additional toxicity, and may improve the efficacy of NAC in HER2-negative breast cancer.
- |||| epirubicin / Generic mfg.
Clinical: New data for an old (though still important) drug. Researchers found a putative mechanism of doxo-mediated cardiotoxicity. It involves heme synthesis and mitochondria. Will it be the same for Epirubicin? Implications for patients are huge. https://t.co/9UFdYEfmMB (Twitter) - Nov 6, 2022
- | epirubicin / Generic mfg.
Journal: Assessing the cardiotoxicity of epirubicin-based chemotherapy in patients with breast cancer using high-sensitivity cardiac troponin T, N-terminal pro b-type natriuretic peptide, and soluble suppression of tumorigenicity-2. (Pubmed Central) - Nov 5, 2022
USMB and chemotherapy can be combined in a clinical setting using commercially available equipment, without additional toxicity, and may improve the efficacy of NAC in HER2-negative breast cancer. Serial measurement of hs-cTnT but not NT-proBNP or sST2 during Epirubicin chemotherapy has important value in the early determination cardiomyocytes damage.
- | epirubicin / Generic mfg.
Journal: A new modality in targeted delivery of epirubicin for tumor theranosis based on PEGylated silver nanoparticles: design, radiolabeling and bioevaluation. (Pubmed Central) - Nov 5, 2022
In addition, I-EPI/PEG/AgNPs showed fast targeting of tumor site by 25.1±0.1 %ID/g within 0.5 h after intravenous injection. Subsequently, the outcomes provided I-EPI/PEG/AgNPs as a new potential system for enhancement of tumor targeting and theranosis (therapy and/or imaging).
- AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma
Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4308;
2 cases of liver function damage was grade 3 (11.8%). Conclusion Camrelizumab combined with AVD has a good effect in the first-line treatment for advanced classical Hodgkin lymphoma, with an objective response rate (ORR) of 100%, and the patients are well tolerated.
- Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
The ZR2-Minichop Study:Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_2484;
Conclusion Camrelizumab combined with AVD has a good effect in the first-line treatment for advanced classical Hodgkin lymphoma, with an objective response rate (ORR) of 100%, and the patients are well tolerated. The ZR2-miniCHOP schedule represented satisfactory efficacy and safety in elderly non-GCB DLBCL.
- GC012F / Gracell
Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma (ENMCC - Great Hall AD) - Nov 4, 2022 - Abstract #ASH2022ASH_1786;
P1/2
GC012F was administered as a single infusion at 3 doses levels (DL) of 1x105/kg, 2x105/kg, or 3x105/kg, after receiving a conditioning chemotherapy consisting of cyclophosphamide and fludarabine...Conclusion In this phase I study for transplant-eligible newly diagnosed high-risk MM, BCMA-CD19 dual FasTCAR-T GC012F showed a very favorable safety profile, high efficacy with 100% ORR and 100% MRD negativity. The promising preliminary results warrants further assessment of GC012F for TE NDMM with more patients and longer follow-up.
- | Imfinzi (durvalumab) / AstraZeneca
Journal: Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. (Pubmed Central) - Nov 2, 2022
P2
Durvalumab added to NACT in TNBC significantly improved survival despite a modest pCR increase and no adjuvant component of durvalumab. Additional studies are needed to clarify the optimal duration and sequence of checkpoint inhibitors in the treatment of early TNBC.
- | Tecentriq (atezolizumab) / Roche
Journal: Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report. (Pubmed Central) - Nov 2, 2022
To our knowledge, this is the first paper to report the use of programmed death-ligand 1 inhibitor, atezolizumab, as treatment for advanced basal cell carcinoma. This case may also be of interest for clinicians when treating patients with two synchronous cancers.